US 12,409,236 B2
Liver-specific nucleic acid regulatory elements and methods and use thereof
Marinee Chuah, Lovenjoel (BE); Thierry Vandendriessche, Lovenjoel (BE); and Pieter De Bleser, Buggenhout (BE)
Assigned to VIB VZW, Ghent (BE); Universiteit Gent, Ghent (BE); and Life Sciences Research Partners VZW, Leuven (BE)
Filed by VIB VZW, Ghent (BE); Life Sciences Research Partners VZW, Leuven (BE); and Universiteit Gent, Ghent (BE)
Filed on Apr. 14, 2023, as Appl. No. 18/300,693.
Application 18/300,693 is a division of application No. 16/659,214, filed on Oct. 21, 2019, granted, now 11,654,201.
Application 16/659,214 is a continuation of application No. 16/175,141, filed on Oct. 30, 2018, granted, now 10,471,157, issued on Nov. 12, 2019.
Application 16/175,141 is a continuation of application No. 15/483,958, filed on Apr. 10, 2017, granted, now 10,149,914, issued on Dec. 11, 2018.
Application 15/483,958 is a continuation of application No. 12/736,584, granted, now 9,617,548, issued on Apr. 11, 2017, previously published as PCT/EP2009/054724, filed on Apr. 21, 2009.
Claims priority of provisional application 61/125,181, filed on Apr. 22, 2008.
Prior Publication US 2023/0293728 A1, Sep. 21, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 48/00 (2006.01); A61K 38/48 (2006.01); C07K 14/81 (2006.01); C12N 9/64 (2006.01); C12N 15/52 (2006.01); C12N 15/63 (2006.01); C12N 15/85 (2006.01); C12N 15/86 (2006.01)
CPC A61K 48/0058 (2013.01) [A61K 38/4846 (2013.01); C07K 14/8121 (2013.01); C12N 9/644 (2013.01); C12N 15/52 (2013.01); C12N 15/63 (2013.01); C12N 15/85 (2013.01); C12N 15/86 (2013.01); C12Y 304/21022 (2013.01); A61K 48/00 (2013.01); C12N 2750/14143 (2013.01); C12N 2799/025 (2013.01); C12N 2799/027 (2013.01); C12N 2830/008 (2013.01); C12N 2830/15 (2013.01); C12N 2830/85 (2013.01)] 17 Claims
 
1. A method of introducing a nucleic acid into a subject, the method comprising administering to the subject a polynucleotide comprising a nucleic acid regulatory element of 90 nucleotides or less operatively linked to a heterologous coding sequence,
wherein the regulatory element enhances liver-specific expression of the heterologous coding sequence as compared to expression of the heterologous coding sequence in the absence of the regulatory element, and
wherein the regulator element comprises SEQ ID NO: 3, or a sequence having at least 95% identity to SEQ ID NO: 3.